GuidelinesEAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction
Introduction
Lower urinary tract symptoms (LUTS) in elderly men were traditionally attributed to the enlarging prostate. The mechanisms invoked were one or all of the following: histologic benign prostatic hyperplasia (BPH), benign prostatic enlargement (BPE), or benign prostatic obstruction (BPO). However, during the last decade the causal link between the prostate and the pathogenesis of LUTS has come into question [1]. Although the enlarged prostate can contribute to the onset of LUTS in a proportion of men >40 yr of age, other factors are of equal importance. Figure 1 illustrates the many causes of LUTS. In any single person complaining of LUTS, it is common for more than one of these factors to be present. This multifactorial view of the aetiology of LUTS has led most experts to regard the whole urinary tract as a single functional unit. This broader, more complex approach to the pathogenesis of LUTS meant that this guidelines panel modified the title (to reflect the change in perspective) from the former “EAU [European Association of Urology] Guidelines on LUTS Suggestive of BPO (BPH)” [2] to the more contemporary and precise “EAU Guidelines on Non-neurogenic Male LUTS Including BPO.”
Because patients seek help for LUTS and not an underlying attribute of the prostate such as BPH or BPE, these updated guidelines have been written from the perspective of men who complain about a variety of bladder storage, voiding, and/or postmicturition symptoms. The recommendations made within the guidelines are based on the best available evidence. These recommendations apply to men ≥40 yr of age who seek professional help for various forms of non-neurogenic benign forms of LUTS, for example, LUTS/BPO, detrusor overactivity/overactive bladder (OAB), or nocturnal polyuria. EAU guidelines on LUTS due to neurologic diseases [3], urinary incontinence [4], urogenital infections [5], ureteral stones [6], or malignant diseases of the lower urinary tract [7] have been published elsewhere.
Section snippets
Evidence acquisition
The recommendations of these guidelines are based on a literature search using articles in the English language published in the PubMed/Medline, Web of Science, and Cochrane databases between 1966 and 31 October 2012, including the search terms lower urinary tract symptoms, benign prostatic hyperplasia, detrusor overactivity, overactive bladder, nocturia, and nocturnal polyuria in combination with the various treatment modalities and the search limits humans, adult men, review, randomised
Conservative treatment
Many men with LUTS are not bothered enough by their symptoms to need drug treatment or surgical intervention. Most of these men can be managed conservatively by a process known as watchful waiting (WW). All men with LUTS should be formally assessed prior to any allocation of treatment. The aim of this assessment is to establish the severity of LUTS and to discriminate the vast majority of men with so-called uncomplicated LUTS that pose no threat to life expectancy from the more unusual
Conclusions
These symptom-oriented guidelines provide practical guidance for the management of men experiencing LUTS. The full version is available online (www.uroweb.org/gls/pdf/12_Male_LUTS.pdf).
References (173)
- et al.
Medical treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia
Eur Urol Suppl
(2009) - et al.
EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines)
Eur Urol
(2004) - et al.
EAU guidelines on neurogenic lower urinary tract dysfunction
Eur Urol
(2009) - et al.
EAU guidelines on assessment and nonsurgical management of urinary incontinence
Eur Urol
(2012) - et al.
2007 guideline for the management of ureteral calculi
J Urol
(2007) - et al.
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update
Eur Urol
(2011) - et al.
Evaluation of patients with bladder outlet obstruction and mild international prostate symptom score followed up by watchful waiting
Urology
(1999) - et al.
State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
Urology
(2004) - et al.
The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study
J Urol
(2008) - et al.
The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT Study
Eur Urol
(2010)
Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia
Urology
Intraoperative floppy iris syndrome associated with tamsulosin
J Cataract Refract Surg
A review of the clinical efficacy and safety of 5a-reductase inhibitors for the enlarged prostate
Clin Ther
Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials
Urology
Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial
Urology
Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia
Urology
Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia
Urology
ARIA3001 ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia
Urology
Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia
Urology
Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies
Urology
Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB
Urology
Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction
J Urol
Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate
Eur Urol
A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms owing to benign prostatic hyperplasia
Eur Urol
Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia [published correction appears in Eur Urol 2011;59:1082]
Eur Urol
Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial
Eur Urol
Desmopressin in the treatment of nocturia: a double-blind, placebo-controlled study
Eur Urol
Clinical experiences with desmopressin for long-term treatment of nocturia
J Urol
A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management—a systematic review and meta-analysis
Eur Urol
Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride
Eur Urol
Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study
Mayo Clin Proc
Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study
J Urol
Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency
J Urol
Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with a-blockers
Eur Urol
The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update
Eur Urol
Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial
Eur Urol
Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement
Eur Urol
The natural history of lower urinary tract dysfunction in men: minimum 10-year urodynamic followup of transurethral resection of prostate for bladder outlet obstruction
J Urol
Antibiotic prophylaxis in urologic procedures: a systematic review
Eur Urol
Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients
J Urol
Bipolar versus monopolar transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials
Eur Urol
Systematic review and meta-analysis of transurethral resection of the prostate versus minimally invasive procedures for the treatment of benign prostatic obstruction
Urology
Midterm results from an international multicentre randomised controlled trial comparing bipolar with monopolar transurethral resection of the prostate
Eur Urol
Four-year outcome of a prospective randomised trial comparing bipolar plasmakinetic and monopolar transurethral resection of the prostate
Eur Urol
Bipolar plasma vaporization vs monopolar and bipolar TURP—a prospective, randomized, long-term comparison
Urology
Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial
Eur Urol
Long-term results of open transvesical prostatectomy from a contemporary series of patients
Urology
Holmium laser enucleation of the prostate versus open prostatectomy for prostates >70 g: 24-month follow-up
Eur Urol
EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU)
Eur Urol
Cited by (943)
Plausible role of oral Fisetin-loaded chitosan oligosaccharide nanoparticles in amelioration of benign prostatic hypertrophy: In vitro and in vivo assessments
2024, Journal of Drug Delivery Science and TechnologyExtracellular nucleotides in smooth muscle contraction
2024, Biochemical PharmacologyChanges in benign prostatic hyperplasia management in Valencia: A real-world evidence analysis
2024, Actas Urologicas Espanolas